Compare KRYS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | PTGX |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 6.4B |
| IPO Year | 2017 | 2016 |
| Metric | KRYS | PTGX |
|---|---|---|
| Price | $299.97 | $100.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $297.60 | $108.23 |
| AVG Volume (30 Days) | 278.4K | ★ 495.3K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 1.83 | 0.05 |
| Revenue | ★ $389,130,000.00 | N/A |
| Revenue This Year | $38.74 | $874.25 |
| Revenue Next Year | $32.53 | N/A |
| P/E Ratio | ★ $160.11 | $1,965.20 |
| Revenue Growth | ★ 33.94 | N/A |
| 52 Week Low | $123.03 | $45.16 |
| 52 Week High | $319.48 | $107.84 |
| Indicator | KRYS | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 58.30 | 50.21 |
| Support Level | $246.17 | $96.20 |
| Resistance Level | N/A | $107.42 |
| Average True Range (ATR) | 13.41 | 4.22 |
| MACD | -0.35 | -0.17 |
| Stochastic Oscillator | 71.16 | 49.60 |
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.